Latest news
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - TradingViewTradingView · Fri, 07 Aug 2026 17:27:00 GMTIMCR: KIMMTRAK's five-year survival data and 16% revenue growth highlight strong performance and pipeline momentum - TradingViewTradingView · Thu, 06 Aug 2026 13:47:38 GMTIMCR: H1 2026 net revenue rose 16% to $223M, with KIMMTRAK's five-year survival data driving growth - TradingViewTradingView · Thu, 06 Aug 2026 13:14:19 GMTUK's Immunocore Q2 EPS misses estimates - TradingViewTradingView · Thu, 06 Aug 2026 11:14:16 GMTIMCR: Q2 2026 revenue up 18% to $115.9M; net loss narrows; pipeline advances in melanoma trials - TradingViewTradingView · Thu, 06 Aug 2026 11:03:02 GMTIs Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? - TradingViewTradingView · Mon, 27 Jul 2026 15:53:00 GMT